New Report Details Oral GLP-1 Patent Race
PatentVest has released a new report analyzing the patent landscape for oral small-molecule GLP-1 drugs. The analysis, based on over 1,200 patent documents, identifies which pharmaceutical programs are building strong exclusivity and which may be vulnerable.
The race to develop a daily pill for weight loss and type 2 diabetes is intensifying, with over 50 oral GLP-1 programs in the works. This new class of drugs aims to replace popular but cumbersome injectables, potentially unlocking a market for the 95% of eligible patients not currently reached. The existing injectable GLP-1 market is already valued at $71 billion. These new oral medications are "small-molecule" drugs, meaning they are chemically synthesized and simpler to produce than the complex biologic-based injectables. This simpler structure allows them to be absorbed through the stomach, offering patients more convenience and potentially lower manufacturing costs for pharmaceutical companies. Eli Lilly is a major contender with its drug, orforglipron. Recent phase 3 trial data showed it was more effective than Novo Nordisk's existing oral drug, Rybelsus, in reducing blood sugar and weight. Lilly has already submitted orforglipron to regulators in over 40 countries and plans for a U.S. submission for type 2 diabetes later this year. Conversely, Pfizer recently halted the development of its promising oral GLP-1 candidate, danuglipron. The decision was made after a study participant experienced potential drug-induced liver injury, highlighting the significant safety hurdles in drug development. Pfizer had previously stopped work on a twice-daily version of the same drug due to side effects. The competition extends beyond the lab and into legal strategy, with companies building extensive patent portfolios to protect their innovations. With patents for blockbuster injectable drugs like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) set to expire in 2031 and 2036 respectively, securing long-term exclusivity for new oral drugs is critical. This intense research and development landscape offers a glimpse into various life science careers. Bioinformatics and computational biology are essential for analyzing the vast datasets from clinical trials, while medicinal chemists work on designing these novel small molecules. The entire process, from discovery to clinical trials and patent law, showcases the diverse intersection of science, technology, and business in bringing a new medicine to patients.
